Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU

被引：0
|
作者：
Katherine A. Lyseng-Williamson
机构：
[1] Adis,
来源：
Drugs & Therapy Perspectives | 2012年 / 28卷 / 12期
关键词：
Multiple Sclerosis; Placebo Recipient; Expand Disability Status Scale; Primary Efficacy Variable; Potassium Channel Blocker;
D O I：
10.1007/BF03262139
中图分类号：
学科分类号：
摘要：
Prolonged-release (PR) fampridine (Fampyra®), a potassium channel blocker, is the first agent to be specifically indicated for the improvement of walking in patients with multiple sclerosis (MS). In clinical trials in patients with MS with impaired walking, PR fampridine 10 mg twice daily improved walking ability to a significantly greater extent than placebo, with improvements being maintained with long-term therapy. PR fampridine 10 mg twice daily is generally well tolerated.
引用
收藏
页码：1 / 4
页数：3
相关论文
共 50 条
  • [21] Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
    Albrecht, Philipp
    Bjorna, Ingrid Kristine
    Brassat, David
    Farrell, Rachel
    Feys, Peter
    Hobart, Jeremy
    Hupperts, Raymond
    Linnebank, Michael
    Magdic, Jozef
    Oreja-Guevara, Celia
    Pozzilli, Carlo
    Salgado, Antonio Vasco
    Ziemssen, Tjalf
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [22] Multiple sclerosis patients with severe walking disability have clinically meaningful improvements in walking speed with prolonged-release fampridine
    Hartung, H. P.
    Goodman, A.
    Putzki, N.
    JOURNAL OF NEUROLOGY, 2011, 258 : 260 - 261
  • [23] QUALITY OF LIFE AMONG PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH PROLONGED-RELEASE FAMPRIDINE 10 MG TABLETS FOR WALKING IMPAIRMENT
    Liu, Y.
    McNeill, M.
    Lee, A.
    Zhong, J.
    Mehta, L. R.
    VALUE IN HEALTH, 2014, 17 (07) : A401 - A402
  • [24] Fingolimod: a guide to its use in multiple sclerosis in the EU
    Lesley J. Scott
    Katherine A. Lyseng-Williamson
    Drugs & Therapy Perspectives, 2012, 28 (10) : 6 - 11
  • [25] Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability
    Esther S. Kim
    Drugs, 2017, 77 : 1593 - 1602
  • [26] Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability
    Kim, Esther S.
    DRUGS, 2017, 77 (14) : 1593 - 1602
  • [27] Prolonged-release fampridine treatment and walking ability and balance in patients with multiple sclerosis: results of the randomized, double-blind MOBILE study
    Mehta, L. R.
    Lycke, J.
    Short, C.
    Gasperini, C.
    Hupperts, R.
    McNeill, M.
    Medori, R.
    Elkins, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 192 - 192
  • [28] Evaluation of gait in patients treated with prolonged-release fampridine in clinical practice
    Preiningerova, J. Lizrova
    Kolarikova, K.
    Havrdova, E.
    JOURNAL OF NEUROLOGY, 2012, 259 : S153 - S153
  • [29] Prolonged-Release Fampridine Treatment and Walking Ability and Balance in Patients with Multiple Sclerosis: Results of the Randomized, Double-Blind MOBILE Study
    Lycke, Jan
    Short, Christine
    Gasperini, Claudio
    Hupperts, Raymond
    McNeil, Manjit
    Medori, Rossella
    Mehta, Lahar
    Elkins, Jacob
    NEUROLOGY, 2014, 83 (02) : E36 - E36
  • [30] Clinical experience using prolonged release fampridine in the symptomatic treatment of multiple sclerosis
    Vaz, Soraia
    Barros, Ariana
    Capela, Carlos
    Sequeira, Joao
    Dias, Sara
    Morgado, Joana
    Sousa, Ary
    Bras, Pedro
    Pedrosas, Rui
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 60 - 60
12345